Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
15 févr. 2023 06h45 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast...
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
19 janv. 2023 07h00 HE
|
Editas Medicine, Inc.
Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and a non-exclusive license for...
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
09 janv. 2023 08h15 HE
|
Editas Medicine, Inc.
Strategic reprioritization of portfolio to focus on hemoglobinopathies and in vivo gene editing Discontinuing internal investments in inherited retinal diseases and in preclinical wholly owned iNK...
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 06h30 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the Company’s President and CEO Gilmore...
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
06 déc. 2022 06h30 HE
|
Editas Medicine, Inc.
EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant Both patients treated with...
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
01 déc. 2022 16h01 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on, Tuesday,...
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
17 nov. 2022 07h15 HE
|
Editas Medicine, Inc.
EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent improvement in BCVA plus additional efficacy endpoints seen in homozygous patients ...
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
02 nov. 2022 06h30 HE
|
Editas Medicine, Inc.
Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial by year-end Completed cell editing and...
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
26 oct. 2022 06h30 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast...
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
13 oct. 2022 06h00 HE
|
Editas Medicine, Inc.
Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement protein levels using a dual vector AAV approach Treated...